CardioMEMS shows real-world heart failure benefit
September 21, 2016|Internal Medicine
Author and Disclosure Information
AT THE HFSA ANNUAL SCIENTIFIC MEETING
The analyses also showed that the impact of PA pressure monitoring on pressure was roughly similar regardless of the left ventricular ejection fraction patients had at baseline, and regardless of their sex.
The registry data were collected by St. Jude, the company that markets the CardioMEMS device. Dr. Abraham is a consultant to St. Jude and was lead investigator for the CHAMPION pivotal trial.
On Twitter @mitchelzoler
